secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revance Therapeutics, Inc. (—)
CIK:        0001479290
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001193125-25-021403
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 2.04, 3.01, 3.03, 5.03, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crown Laboratories completes acquisition of Revance Therapeutics for $3.65/share
--------------------------------------------------------------------------------

- Crown Labs acquired Revance at $3.65/share cash; ~82% of shares tendered in offer.
- Merger completed Feb 6, 2025; Revance becomes wholly-owned subsidiary.
- 1.75% convertible notes due 2027 now convertible only into $3.65/unit cash (no stock).
- All eight directors resigned; Jeffery Bedard named sole director; new officers appointed.
- Revance common stock to be delisted from Nasdaq and deregistered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479290/000119312525021403/0001193125-25-021403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479290/000119312525021403/d914912d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-021403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer